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Background
Late onset degenerative dementia is a growing, common
and complex disorder in which the aetiological role
played by environment and genes has not yet been
established. A familial component is frequently ascer-
tained in Alzheimer’s disease (AD) (30% of first degree
relatives affected) and also in Frontotemporal Dementia
(FTD) (40-60%).
Early onset degenerative dementia has sometimes been
recognized as caused by autosomal dominant genes, Pre-
senilines (PS1 and PS2) and the Amyloid Precursor Pro-
tein (APP) in AD, whereas in Frontotemporal dementia,
two major genes (Microtubule Associated Protein tau,
MAPT and Progranulin, PGRN) have also been
identified.
PS1 and MAPT mutations have been identified also in
in very early onset patients (PS1 24 years [1], MAPT 22
years [2]), but also in late onset patients (PS1 78 years
[3], MAPT 75 years [4] 87 years [5].
To evaluate whether FAD and PGRN gene mutations
account for late onset dementia.
Materials and methods
Late onset familial dementia patients (onset >65 years)
were regularly diagnosed in our centre.
Diagnosis of dementia was performed through a
detailed clinical assessment. The NINCDS-ADRDA and
Lund-Manchester group criteria were used for diagnosis
of AD and FTD respectively.
Molecular screening of PS1, PS2, APP and PGRN
genes was performed.
Results
A PS2 Ser130Leu [6] and a novel PS2 Val139Met [7]
mutations have been found in two late onset AD cases
with onset at 83 and 76.
Three more unrelated cases with an APP A713T
mutation showed an onset age between 73 and 82 years
[8]. A novel PGRN c1145insA has been identified in a
FTD patient of 87 years belonging to a pedigree whose
age at onset spans from 35 to 87 [5].
Conclusions
Several autosomal dominant genes, either in AD or in
FTD show an impact on late onset dementia. Heritabi-
lity in late onset forms is now more evident, probably
due to longer life survival. It is possible that mutation
frequency has been underestimated due to the lack of
wide genetic epidemiology. Genetic screening of FAD
and PGRN genes might be recommended in familial late
onset dementia as a part of Multidimensional evaluation.
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